2015 ASCO Journal Club: Breast Cancer Fourth Quarter

Each quarter, ASCO’s experts review the leading journals, including the Journal of Clinical Oncology, to compile the most relevant, practice-changing science in breast cancer. Reviews are presented in a didactic slide format, with audio commentary and links to references and resources and will focus on the following areas: translational science, clinical trials, reviews, guidelines, and editorials.

Articles covered in this quarter’s review include:

  • Metzger Filho O, Giobbie-Hurder A, Mallon E, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol. 2015 Sep 1;33(25):2772-9.
  • Keenan T, Moy B, Mroz EA, et al. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.  J Clin Oncol. 2015 Nov 1;33(31):3621-7.
  • Martín M, Ruiz Simón A, Ruiz Borrego M, et al. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. J Clin Oncol. 2015 Nov 10;33(32):3788-95.

Learning Objectives

  • Discuss the magnitude and benefit of endocrine treatment options by histologic subtype of early stage breast cancers
  • Explain the racial differences in breast tumor genomic characteristics in African American and white women
  • Analyze the efficacy of substituting cyclophosphamide for capecitabine in the adjuvant treatment of breast cancer
  • Apply knowledge learned to enhance the care delivered to patients with breast cancer

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes
  • This course expires on December 16, 2018. Participants must complete all necessary course components by this date to receive credit.